Research & Development
Research & Development
Chemomab’s R&D experts, infrastructure and capabilities support early-stage discovery through clinical development. Our R&D team has investigated the underlying biology of the fibro-inflammatory cycle using a broad range of in-vitro and in-vivo models, which have provided the foundation for development of potentially transformative patient therapeutics.
Chemomab leverages collaborations with leading investigators from prestigious research centers around the world to obtain further evidence on CCL24’s unique role in fibrosis and inflammations and demonstrate nebokitug’s potential anti-fibrotic and anti-inflammatory therapeutic effects.
Over the last 15 years, our scientific team discovered the role of the soluble protein CCL24 as a key regulator in fibro-inflammatory processes, specifically, its pivotal pro-fibrotic and pro-inflammatory effects in fibrotic diseases.
Chemomab researchers have documented CCL24 up-regulation and its correlation with disease severity in fibrotic disease tissues, including liver, skin and lung fibrosis-related pathologies. Based on these discoveries, Chemomab established a comprehensive preclinical package to support the therapeutic effects of blockading CCL24.
Nebokitug is a first-in-class dual activity monoclonal antibody that neutralizes CCL24, a soluble protein that helps drive the inflammatory and fibrotic pathways central to primary sclerosing cholangitis and other fibro-inflammatory diseases. By inhibiting CCL24, nebokitug blocks immune cell recruitment and fibroblast activation, thereby interrupting the self-reinforcing cycle that results in fibrosis. In clinical and preclinical studies, nebokitug has been shown to have a favorable safety profile, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases.
PSC is a rare, debilitating progressive liver disease characterized by inflammation and fibrosis (scarring) of the bile ducts that can lead to cirrhosis of the liver, liver failure and death.